Track and Trace Gains Prominence in the War Against Counterfeit Drugs
Regulation and technology lead the fight against counterfeit pharmaceuticals.
By Franz Ludwig, Bosch Packaging Technology
Counterfeit pharmaceuticals are a major ongoing threat to patients and pharmaceutical manufacturers alike. Not only do they result in reduced treatment efficacy and sometimes failure, but they also harm manufacturer reputations, reduce revenues and lower return on investment (ROI) in research and development. In fact, they are responsible for an estimated 2,000 deaths daily worldwide and represent a grey industry anticipated to be worth up to $205 billion touching Europe, America, Japan and emerging markets .
The problem is worsening. According to a directive from the European Union, the number of counterfeit medicines seized at its outer border has tripled between 2006 and 2009 to reach approximately 7.5 million items, not including patent issues . More alarmingly, whereas the issue of counterfeit pharmaceuticals was previously primarily related to lifestyle medicines, now innovative and life-saving drugs are increasingly falsified, with dangerous implications for the patients who rely on these drugs to survive .
As the counterfeit drug problem continues to grow with widespread media attention, public confidence in public health systems as well as in pharmaceutical brands is eroding. There is an urgent need to understand why and how the counterfeit drug market evolved, as well as for governments and pharmaceutical manufacturers to unite to implement programs that protect consumers. Advances in regulations and track and trace technology are proving to be the solutions needed to combat this deadly and costly challenge.
An evolving and threatening black market
Over the past few decades, various factors have contributed to the growth in counterfeit drugs.
Due to globalization, regional economies, societies, and cultures have become integrated through communication, transportation and trade, making it easier for counterfeiters to trade and transport falsified drugs. Additionally, the economic crisis had a global effect, leading cash-strapped consumers to find more cost-effective pharmaceutical sources, which served to bolster counterfeiting in the healthcare industry.
The rise of the Internet has also facilitated the purchasing of counterfeit drugs. Over 50 percent of medicines purchased on the Internet from illegal websites that conceal their physical addresses have been found to be counterfeit . However, counterfeit products increasingly find their way into the legal supply chain . Previously, online pharmacies were traditional targets, where counterfeit drugs were typically sold in small quantities to individuals, resulting in only limited gain for counterfeiters. Now, counterfeiters are switching their focus to pharmaceutical wholesalers supplying medicines worth hundreds of thousands of pounds, euros or dollars traded in a single transaction, causing more widespread damage and public affliction.
Counterfeiting is most prevalent in regions where regulatory and enforcement systems for medicines are weakest. In developing countries, one in four medicines sold in street markets is estimated to be counterfeit, according to the World Health Organization (WHO .
Protecting patients and preserving brands
Pharmaceutical manufacturers, industry suppliers and governments have been uniting to combat counterfeit drugs. While international regulations and guidelines have been developed to help accomplish this, regional and local regulations vary at present. To address this issue new EU Serialization will be introduced in 2014 followed by the new FDA/California Serialization standard in 2015. Both of these initiatives aim to harmonize coding and require manufacturer to implement serialization systems. Additionally, the World Health Organization (WHO) has established the IMPACT (International Medical Products Anti-Counterfeiting Taskforce) initiative, involving a range of stakeholders in collaborative efforts to protect consumers from buying and using counterfeit products . Further, international institutions such as Interpol, the World Customs Organization (WCO) and The European Directorate for the Quality of Medicines (EDQM) are working closely with governments and companies to create a global security system and strengthen regulations.
As globalization has created more steps between production and consumption of pharmaceuticals, manufacturers have implemented various approaches to detect and prevent counterfeit products. A combination of anti-tamper, serialization and authentication technologies can be used to detect real versus counterfeit products, creating several layers of security for original pharmaceutical producers.
Anti-tampering is the first step in any brand-protection strategy. It can be achieved by designing packaging with features like perforated openings. Serialization is the second layer of protection, relying on printing on each package a unique serial number that is recorded at production in a database. Any subsequent packs with the same serial number will be flagged as suspect. Finally, authentication serves as the third layer of protection with overt, covert and forensic methods. Overt methods such as visible holograms or color-shifting can be used on product packaging, whereas covert methods like infrared and ultraviolet pigments and microtext can be read with specialized equipment. Products using forensic authentication solutions, such as molecular markers and biological tracers, must be tested in laboratories.
Track and trace is one method of serialization to help managers protect against counterfeiting and expiration throughout the supply chain. Its advantage is that it enables the serial number to be recorded at various points throughout the supply chain on a central server or on the product itself; facilitating the discovery of where counterfeit products have entered the supply chain. It also allows full traceability of products on a global basis.